Treace Medical Concepts, Inc. TMCI
4.28 USD +0.01 (+0.23%)
At closeNov 3, 2026, 5:50 PM EST
4.25 -0.03 -0.70%
After hours · Nov 3, 5:50 PM ET
4.21 Day range 4.38
1.17 52-week range 6.58
- YTD
- +74.69%
- 1 year
- -35.05%
- Market cap
- 278.35M
- Revenue (ttm)
- 202.86M
- Profit margin
- -30.33%
- EPS (ttm)
- -0.92
- Shares out
- 62.30M
- Forward P/E
- -9.28
- YTD return
- +74.69%
- 1-year return
- -35.05%
- Volume
- 211.16K
- Avg volume
- 282.03K
- Open
- 4.28
- Previous close
- 4.27
- Day's range
- 4.21 – 4.38
- 52-week range
- 1.17 – 6.58
- Beta
- 0.24
- Analysts
- Hold
- Price target
- 7.96 (+86.0%)
- Earnings date
- Aug 6, 2024
2Y -1.15 (-21.18%)
Key statistics
- Enterprise value
- 420.91M
- PEG ratio
- 0.00
- Price / sales
- 2.14
- Price / book
- 4.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 10.60%
- Free cash flow
- -20.63M
- Total cash
- 82.80M
- Total debt
- 70.12M
- Return on equity
- -50.69%
- Short % of float
- 5.32%
- 50-day average
- 6.87
- 200-day average
- 7.45
Analyst view
Consensus: hold
Hold
Price target (mean) 7.96 +86.0% upside
Now 4.28
- Target (low)
- 7.50
- Target (mean)
- 7.96
- Target (high)
- 8.40
Ratings (0m) 6 0 buy · 6 hold · 0 sell
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.04032.
Financials — quick view
TMCI Revenue — quarterly 45.38M
TMCI Net income — quarterly -15.87M
TMCI EPS — quarterly -0.24
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.27 | -0.25 | +0.02 | +7.41% |
| Aug 6, 2024 | Jun 1, 2024 | -0.29 | -0.34 | -0.05 | -17.24% |
| Aug 6, 2024 | Jun 1, 2024 | -0.29 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.30 | -0.30 | 0.00 | 0.00% |
| May 7, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| Feb 27, 2024 | Dec 1, 2023 | -0.09 | -0.10 | -0.01 | -11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | Truist Securities | main | Hold | Hold |
| Nov 6, 2024 | Stifel | main | Hold | Hold |
| Oct 14, 2024 | Truist Securities | main | Hold | Hold |
| Aug 7, 2024 | UBS | main | Neutral | Neutral |
| Aug 7, 2024 | Truist Securities | main | Hold | Hold |
| Jul 16, 2024 | Truist Securities | main | Hold | Hold |
About Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- treace.com
News
Treace to Present at the Stifel 2026 Healthcare Conference 
Treace to Report Third Quarter 2026 Financial Results on November 6, 2026 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders? 
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders? 
Treace Medical Presents 5-Year ALIGN3D Data Showing 0.8% Recurrence Rate Alongside MTA3D And SPRINT Clinical Results At AOFAS 2026 
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure 
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting 
Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $5 
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on TMCI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKEWELL JOHN K | Director | Stock Award(Grant) | May 20, 2024 | 492,439 |
| BERRY LANCE A | Director | Stock Award(Grant) | May 20, 2024 | 20,676 |
| BERUTTI AARON | Officer | Stock Award(Grant) | Aug 8, 2024 | 165,791 |
| ELDER SCOT MICHAEL | Officer | Stock Award(Grant) | Nov 10, 2024 | 449,678 |
| HAIR MARK | Chief Financial Officer | Stock Award(Grant) | Aug 8, 2024 | 369,115 |
| HAMILTON LAWRENCE W | Director | Stock Award(Grant) | May 20, 2024 | 20,139 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.95% | 6,196,000 | 43.12M | Sep 29, 2024 |
| Blackrock Inc. | 6.71% | 4,182,320 | 29.11M | Sep 29, 2024 |
| Morgan Stanley | 5.26% | 3,274,057 | 22.79M | Sep 29, 2024 |
| Vanguard Group Inc | 4.40% | 2,741,488 | 19.08M | Sep 29, 2024 |
| William Blair Investment Management, LLC | 3.84% | 2,392,061 | 16.65M | Sep 29, 2024 |
| Deutsche Bank Aktiengesellschaft | 3.30% | 2,056,816 | 14.32M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.34% | 1,458,503 | 10.15M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.00% | 1,245,472 | 8.67M | Oct 30, 2024 |
| Blair (William) Mutual Funds, Inc.-Small Cap Growth Fund | 1.35% | 842,614 | 5.86M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.08% | 674,760 | 4.70M | Sep 29, 2024 |
| Buffalo Small Cap Fund | 0.85% | 526,918 | 3.67M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.81% | 501,705 | 3.49M | Aug 30, 2024 |